The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

被引:4
作者
Tan, Grace Hwei Ching [1 ]
Shannon, Nicholas B. [2 ]
Chia, Claramae Shulyn [1 ]
Lee, Lui Shiong [3 ]
Soo, Khee Chee [1 ]
Teo, Melissa Ching Ching [1 ]
机构
[1] Natl Canc Ctr Singapore, Div Surg Oncol, Singapore, Singapore
[2] Duke NUS Med Sch, Singapore, Singapore
[3] Singapore Gen Hosp, Dept Urol, Singapore, Singapore
关键词
Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal carcinomatosis; Urological procedures; Urological reconstruction;
D O I
10.1016/j.ajur.2017.09.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are increasingly being used to treat peritoneal malignancies. Urological resections and reconstruction (URR) are occasionally performed during the surgery. We aim to evaluate the impact of these procedures on peri-operative outcomes of CRS and HIPEC patients. Methods: A retrospective review of a prospectively maintained database of all patients who underwent CRS-HIPEC from April 2001 to February 2016 was performed. Outcomes between patients who had surgery involving, and not involving URR were compared. Primary outcomes were the rate of major complications and the duration of stay in the intensive care unit (ICU) and hospital. Secondary outcomes were that of overall survival (OS) and prognostic factors that would indicate a need for URR. Results: A total of 214 CRS-HIPEC were performed, 21 of which involved a URR. Baseline clinical characteristics did not vary between the groups (URR vs. No URR). Urological resections comprised of 52% bladder resections, 24% ureteric resections, and 24% involving both bladder and ureteric resections. All bladder defects were closed primarily while ureteric reconstructions consisted of two end-to-end anastomoses, one ureto-uretostomy, five direct implantations into the bladder and three boari flaps. URR were more frequently required in patients with colorectal peritoneal disease (p = 0.029), but was not associated with previous pelvic surgery (76% vs. 54%, p = 0.065). Patients with URR did not suffer more serious complications (14% vs. 24%, p = 0.42). ICU (2.2 days vs. 1.4 days, p = 0.51) and hospital stays (18 days vs. 25 days, p = 0.094) were not significantly affected. Undergoing a URR did not affect OS (p = 0.99), but was associated with increased operation time (570 min vs. 490 min, p = 0.046). Conclusion: While concomitant URR were associated with an increase in operation time, there were no significant differences in postoperative complications or OS. Patients with colorectal peritoneal metastases are more likely to require a URR compared to other primary tumours, and needs to be considered during pre-operative planning. (C) 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:194 / 198
页数:5
相关论文
共 18 条
[1]  
Braam HJ, 2015, ANTICANCER RES, V35, P295
[2]   Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer [J].
Di Giorgio, Angelo ;
Naticchioni, Enzo ;
Biacchi, Daniele ;
Sibio, Simone ;
Accarpio, Fabio ;
Rocco, Monica ;
Tarquini, Sergio ;
Di Seri, Marisa ;
Ciardi, Antonio ;
Montruccoli, Daniele ;
Sammartino, Paolo .
CANCER, 2008, 113 (02) :315-325
[3]  
Dindo D, 2004, ANN SURG, V244, P931
[4]   Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study [J].
Glehen, O ;
Kwiatkowski, F ;
Sugarbaker, PH ;
Elias, D ;
Levine, EA ;
De Simone, M ;
Barone, R ;
Yonemura, Y ;
Cavaliere, F ;
Quenet, F ;
Gutman, M ;
Tentes, AAK ;
Lorimier, G ;
Bernard, JL ;
Bereder, JM ;
Porcheron, J ;
Gomez-Portilla, A ;
Shen, P ;
Deraco, M ;
Rat, P ;
Gilly, FN .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3284-3292
[5]   HIPEC for Peritoneal Carcinomatosis: Does an Associated Urologic Procedure Increase Morbidity? [J].
Honore, C. ;
Souadka, A. ;
Goere, D. ;
Dumont, F. ;
Deschamps, F. ;
Elias, D. .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) :104-109
[6]   Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis secondary to urachal adenocarcinoma [J].
Krane, L. Spencer ;
Kader, A. Karim ;
Levine, Edward A. .
JOURNAL OF SURGICAL ONCOLOGY, 2012, 105 (03) :258-260
[7]   Genitourinary Resection at the Time of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis Is Not Associated with Increased Morbidity or Worsened Oncologic Outcomes: A Case-matched Study [J].
Leapman, Michael S. ;
Jibara, Ghalib ;
Tabrizian, Parissa ;
Franssen, Bernardo ;
Yang, Ming-Jim ;
Romanoff, Anya ;
Hall, Simon J. ;
Palese, Michael ;
Sarpel, Umut ;
Hiotis, Spiros ;
Labow, Daniel .
ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (04) :1153-1158
[8]   Effect of a concomitant urologic procedure on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy [J].
Lyon, Timothy D. ;
Turner, Robert M., II ;
Nikonow, Tara N. ;
Wang, Li ;
Uy, Jamie ;
Ramalingam, Lekshmi ;
Holtzman, Matthew P. ;
Pingpank, James F. ;
Bartlett, David L. ;
Davies, Benjamin J. .
JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (02) :218-222
[9]  
R Core Team, 2020, R LANG ENV STAT COMP
[10]  
Sadeghi B, 2000, CANCER-AM CANCER SOC, V88, P358, DOI 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.3.CO